Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma

We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 62.4 %. 33.2 % patients achieved complete remission (...

Full description

Bibliographic Details
Main Authors: S. S. Bessmeltsev, L. V. Stelmashenko, N. V. Stepanova, K. M. Abdulkadyrov, G. N. Salogub, E. R. Machulaitene, E. V. Kariagina
Format: Article
Language:Russian
Published: ABV-press 2022-11-01
Series:Онкогематология
Subjects:
bortezomib
multiple myeloma
initial treatment
complete remission
overall survival
neuropathy
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/711

Internet

https://oncohematology.abvpress.ru/ongm/article/view/711

Similar Items